Search

Your search keyword '"Herring W.L."' showing total 2 results
Start Over Author "Herring W.L." Publication Year Range Last 3 years
2 results on '"Herring W.L."'

1. Cost-effectiveness models for Alzheimer's disease and related dementias

Author

Handels, R.L.H., Green, C., Gustavsson, A., Herring, W.L., Winblad, B., Wimo, A., Skoldunger, A., Karlsson, A., Anderson, R., Belger, M., Bruck, C., Espinosa, R., Hlavka, J.P., Jutkowitz, E., Lin, P.J., Mendez, M.L., Mar, J., Shewmaker, P., Spackman, E., Tafazzoli, A., Tysinger, B., Jonsson, L., IPECAD, Modeling, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Psychology 2, and Public Health

Subjects
model validation, COMPLICATIONS, TRANSPARENCY, decision-analytic modeling, economic evaluation, Epidemiology, IMPACT, Health Policy, MORTALITY, EDUCATION, Alzheimer's disease, VALIDATION, PREVALENCE, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, SDG 3 - Good Health and Well-being, ECONOMIC EVALUATIONS, RA0421 Public health. Hygiene. Preventive Medicine, Cross-comparison, Dementia, Neurology (clinical), HEALTH, Geriatrics and Gerontology, HOOD CHALLENGE
Abstract

INTRODUCTION: The credibility of model-based economic evaluations of Alzheimer's disease (AD) interventions is central to appropriate decision-making in a policy context. We report on the International PharmacoEconomic Collaboration on Alzheimer's Disease (IPECAD) Modeling Workshop Challenge.METHODS: Two common benchmark scenarios, for the hypothetical treatment of AD mild cognitive impairment (MCI) and mild dementia, were developed jointly by 29 participants. Model outcomes were summarized, and cross-comparisons were discussed during a structured workshop.RESULTS: A broad concordance was established among participants. Mean 10-year restricted survival and time in MCI in the control group ranged across 10 MCI models from 6.7 to 9.5 years and 3.4 to 5.6 years, respectively; and across 4 mild dementia models from 5.4 to 7.9 years (survival) and 1.5 to 4.2 years (mild dementia).DISCUSSION: The model comparison increased our understanding of methods, data used, and disease progression. We established a collaboration framework to assess cost-effectiveness outcomes, an important step toward transparent and credible AD models.

Published
2023

2. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

Author

Spelman T., Herring W. L., Zhang Y., Tempest M., Pearson I., Freudensprung U., Acosta C., Dort T., Hyde R., Havrdova E., Horakova D., Trojano M., De Luca G., Lugaresi A., Izquierdo G., Grammond P., Duquette P., Alroughani R., Pucci E., Granella F., Lechner-Scott J., Sola P., Ferraro D., Grand'Maison F., Terzi M., Rozsa C., Boz C., Hupperts R., Van Pesch V., Oreja-Guevara C., van der Walt A., Jokubaitis V. G., Kalincik T., Butzkueven H., Luca G., UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Service de neurologie, Spelman T., Herring W.L., Zhang Y., Tempest M., Pearson I., Freudensprung U., Acosta C., Dort T., Hyde R., Havrdova E., Horakova D., Trojano M., De Luca G., Lugaresi A., Izquierdo G., Grammond P., Duquette P., Alroughani R., Pucci E., Granella F., Lechner-Scott J., Sola P., Ferraro D., Grand'Maison F., Terzi M., Rozsa C., Boz C., Hupperts R., Van Pesch V., Oreja-Guevara C., van der Walt A., Jokubaitis V.G., Kalincik T., Butzkueven H., and Luca G.

Subjects
Pharmacology, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Fingolimod Hydrochloride, Cost-Benefit Analysis, Natalizumab, Health Policy, Public Health, Environmental and Occupational Health, Humans, multiple sclerosis, effectiveness, cost, natalizumab, fingolimod, Immunosuppressive Agents
Abstract

Background: Patients with highly active relapsing-remitting multiple sclerosis inadequately responding to first-line therapies (interferon-based therapies, glatiramer acetate, dimethyl fumarate, and teriflunomide, known collectively as “BRACETD”) often switch to natalizumab or fingolimod. Objective: The aim was to estimate the comparative effectiveness of switching to natalizumab or fingolimod or within BRACETD using real-world data and to evaluate the cost-effectiveness of switching to natalizumab versus fingolimod using a United Kingdom (UK) third-party payer perspective. Methods: Real-world data were obtained from MSBase for patients relapsing on BRACETD in the year before switching to natalizumab or fingolimod or within BRACETD. Three-way-multinomial-propensity-score–matched cohorts were identified, and comparisons between treatment groups were conducted for annualised relapse rate (ARR) and 6-month–confirmed disability worsening (CDW6M) and improvement (CDI6M). Results were applied in a cost-effectiveness model over a lifetime horizon using a published Markov structure with health states based on the Expanded Disability Status Scale. Other model parameters were obtained from the UK MS Survey 2015, published literature, and publicly available UK sources. Results: The MSBase analysis found a significant reduction in ARR (rate ratio [RR]=0.64; 95% confidence interval [CI] 0.57–0.72; p&nbsp

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results